Kevin A. Cassady, MD :: Nationwide Children's Hospital, Columbus, Ohio

Kevin A. Cassady, MD

Kevin A. Cassady, MD Best Doctors 2011-2012

Contact Information

Infectious Diseases
700 Children's Dr
Columbus, OH 43205 [ map ]
PH: (614) 722-4450
FX: (614) 722-4458

Biography

Dr. Cassady earned his bachelor's degree from Georgetown University in Washington, D.C., followed by his MD from the University of Alabama School of Medicine in Birmingham, Alabama. He completed his residency in Pediatrics at the University of Washington in Seattle, as well as a research and clinical Infectious Disease fellowships as part of the Pediatric Scientist Development Program at the University of Chicago and the University of Alabama in Birmingham (UAB).

Dr. Cassady then conducted research as an Associate Scientist at the Comprehensive Cancer Center at UAB (1999-2015), before joining as a faculty member for Pediatric Infectious Diseases (2010-2015); Cell, Development and Integrative Biology (2011-2015); and the Graduate Biomedical Science program (2012-2015) at UAB as an Associate Professor and then an Associate Professor with tenure (2012-2015). In 2015, Dr. Cassady joined the faculty at The Research Institute at Nationwide Children's Hospital as a principal investigator in the Center for Childhood Cancer and Blood Diseases, in addition to joining the Pediatric Infectious Diseases team at Nationwide Children's as a physician.

Gender:

  • Male

Languages Spoken:

  • English

Research Interests

Research Center:

Areas of Interest:

  • Dr. Cassady's research focuses on the pathogenic mechanisms by which Herpes simplex virus (HSV) and Human Cytomegalovirus (HCMV) evade immune recognition in infected cells. He has studied HSV virology for almost 20 years.

    Specifically, Dr. Cassady has focused on how HSV induces and modulates antiviral interferon signaling proteins during the initial hours of infection and how this limits viral replication and neurovirulence. These studies led to the development of an avirulent HSV/HCMV chimeric virus as an anti-tumor therapeutic. Preclinical studies show that the chimeric HSV is superior to first generation HSV oncolytic viruses. In addition to the improved viral replication and tumor cell lysis, differences in the adaptive immune response also contribute to C134 efficacy.

    The Chimeric HSV has been produced by the NExT program as clinical grade product and it has successfully completed FDA-requested biotoxicology studies, Recombinant DNA Advisory Council (RAC) review, and is pending FDA IND approval for Phase I study in patients with recurrent Glioblastoma multiforme (GBM). In addition to advancing C134 to Phase I clinical trial, Dr. Cassady is investigating ways to improve C134 anti-tumor activity by harnessing the antiviral immune response and priming tumor antigen recognition.

Education and Training

Medical School

  • University of Alabama
    Date Completed: 06/30/1991

Residency

  • Seattle Children's Hospital
    Date Completed: 06/30/1994

Fellowship

  • Children's of Alabama and University of Alabama at
    Date Completed: 07/31/1995

Fellowship

  • Children's of Alabama
    Date Completed: 03/31/1999

Department:

  • Pediatrics

Section:

  • Infectious Diseases

Specialty:

  • Pediatric Infectious Diseases
  • Pediatrics

Date of Appointment at Nationwide Children’s Hospital:

  • 07/06/2015

Publications

  • Friedman,G,K; Nan,L; Haas,M,C; Kelly,V,M; Moore,B,P; Langford,C,P; Xu,H; Han,X; Beierle,E,A; Markert,J,M; Cassady,K,A; Gillespie,G,Y. 2015. gamma(1)34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.  GENE THERAPY. Vol. 22, no. 4. (April): 348-355.
  • Roth,Justin,C; Cassady,Kevin,A; Cody,James,J; Parker,Jackie,N; Price,Kathleen,H; Coleman,Jennifer,M; Peggins,James,O; Noker,Patricia,E; Powers,Nicholas,W; Grimes,Sheila,D; Carroll,Steven,L; Gillespie,G,Yancey; Whitley,Richard,J; Markert,James,M. 2014. Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates.  HUMAN GENE THERAPY CLINICAL DEVELOPMENT. Vol. 25, no. 1. (March): 16-27.
  • Cassady KA and Whitley RJ. 2014. Pathogenesis and Pathophysiology of Viral Infections of the Central Nervous System. In Infections of the Central Nervous System. 4th ed. Philadelphia: Lippincott Williams and Wilkins.
  • Gaston,David,C; Odom,Carl,I; Li,Li; Markert,James,M; Roth,Justin,C; Cassady,Kevin,A; Whitley,Richard,J; Parker,Jacqueline,N. 2013. Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1.  PLOS ONE. Vol. 8, no. 11. (November): ee81768.
  • Friedman,Gregory,K; Raborn,Joel; Kelly,Virginia,M; Cassady,Kevin,A; Markert,James,M; Gillespie,G,Yancey. 2013. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.  Frontiers in oncology. Vol. 3, no. January: 28-?.
  • Friedman,Gregory,K; Haas,Marilyn,C; Kelly,Virginia,M; Markert,James,M; Gillespie,George,Yancey; Cassady,Kevin,A. 2012. Hypoxia Moderates gamma(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.  TRANSLATIONAL ONCOLOGY. Vol. 5, no. 3. (June): 200-207.
  • Friedman,Gregory,K; Cassady,Kevin,A; Beierle,Elizabeth,A; Markert,James,M; Gillespie,G,Yancey. 2012. Targeting pediatric cancer stem cells with oncolytic virotherapy.  PEDIATRIC RESEARCH. Vol. 71, no. 4. (April): 500-510.
  • Odom,Carl,I; Gaston,David,C; Markert,James,M; Cassady,Kevin,A. 2012. Human herpesviridae methods of natural killer cell evasion.  Advances in virology. Vol. 2012, no. January: 359869-?.
  • Cassady,Kevin,A; Saunders,Ute; Shimamura,Masako. 2012. Delta gamma(1)34.5 Herpes Simplex Viruses Encoding Human Cytomegalovirus IRS1 or TRS1 Induce Interferon Regulatory Factor 3 Phosphorylation and an Interferon-Stimulated Gene Response.  JOURNAL OF VIROLOGY. Vol. 86, no. 1. (January): 610-614.
  • Shimamura,Masako; Saunders,Ute; Rha,Brian; Guo,Lingling; Cassady,Kevin,A; George,James,F; Britt,William,J. 2011. Ganciclovir Transiently Attenuates Murine Cytomegalovirus-Associated Renal Allograft Inflammation.  TRANSPLANTATION. Vol. 92, no. 7. (October): 759-766.
  • Parker,Jacqueline,N; Zheng,Xiaojia; Luckett,William; Markert,James,M; Cassady,Kevin,A. 2011. Strategies for the Rapid Construction of Conditionally-Replicating HSV-1 Vectors Expressing Foreign Genes as Anticancer Therapeutic Agents.  MOLECULAR PHARMACEUTICS. Vol. 8, no. 1. (January): 44-49.
  • Cassady,Kevin,A; Parker,Jacqueline,Nuss. 2010. Herpesvirus vectors for therapy of brain tumors.  The open virology journal. Vol. 4, no. January: 103-108.
  • Cassady KA. 2010. Infections of the Central Nervous System - Viral. In Antibiotic and Chemotherapy. 9th ed. Edinburgh: Churchill Livingstone.
  • Shah,Amish,C; Parker,Jacqueline,N; Shimamura,Masako; Cassady,Kevin,A. 2009. Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response.  VIRUSES-BASEL. Vol. 1, no. 3. (December): 510-522.
  • Friedman,Gregory,K; Langford,Catherine,P; Coleman,Jennifer,M; Cassady,Kevin,A; Parker,Jacqueline,N; Markert,James,M; Gillespie,G,Yancey. 2009. Engineered herpes simplex viruses efficiently infect and kill CD133+human glioma xenograft cells that express CD111.  JOURNAL OF NEURO-ONCOLOGY. Vol. 95, no. 2. (November): 199-209.
  • Cassady, KA and Whitley RJ. 2009. Viral Central Nervous System Infections. In Clinical virology. 3rd ed. Washington, DC: ASM Press.
  • Bryan,Coleman,J; Prichard,Mark,N; Daily,Shannon; Jefferson,Geraldine; Hartline,Caroll; Cassady,Kevin,A; Hilliard,Lee; Shimamura,Masako. 2008. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma.  PEDIATRIC INFECTIOUS DISEASE JOURNAL. Vol. 27, no. 10. (October): 946-948.
  • Shah,A,C; Parker,J,N; Gillespie,G,Y; Lakeman,F,D; Meleth,S; Markert,J,M; Cassady,K,A. 2007. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.  GENE THERAPY. Vol. 14, no. 13. (July): 1045-1054.
  • Guffey,M,Brad; Dalzell,Alex; Kelly,David,R; Cassady,Kevin,A. 2007. Ulceroglandular tularemia in a nonendemic area.  SOUTHERN MEDICAL JOURNAL. Vol. 100, no. 3. (March): 304-308.
  • Shah,Amish,C; Price,Kathleen,H; Parker,Jacqueline,N; Samuel,Sharon,L; Meleth,Sreelatha; Cassady,Kevin,A; Gillespie,G,Yancey; Whitley,Richard,J; Markert,James,M. 2006. Serial passage through human glioma xenografts selects for a Delta gamma(1)34.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.  JOURNAL OF VIROLOGY. Vol. 80, no. 15. (August): 7308-7315.
  • Cassady KA. 2006. Congenital Lymphocytic Choriomeningitis Virus Infection. In Congenital and Perinatal Infection: a Concise Diagnosis. 1st ed. N/A: Humana Press.
  • Cassady,K,A. 2005. Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection.  JOURNAL OF VIROLOGY. Vol. 79, no. 14. (July): 8707-8715.
  • Cassady KA and Whitley RJ. 2004. Pathogenesis and Pathophysiology of Viral Infections of the Central Nervous System. In Infections of the Central Nervous System. 3rd ed. Philadelphia: Lippincott Williams and Wilkins.
  • Cassady KA, Gnann JW and Whitley RJ. 2003. Viral Infections of the Central Nervous System. In Therapy of Infectious Diseases. 1st ed. Philadelphia: Saunders.
  • Cassady KA. 2003. Infections of the Central Nervous System - Viral. In Antibiotic and Chemotherapy. 8th ed. Edinburgh: Churchill Livingstone.
  • Cassady,K,A; Gross,M. 2002. The herpes simplex virus type 1 U(s)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain.  JOURNAL OF VIROLOGY. Vol. 76, no. 5. (March): 2029-2035.
  • Cassady,K,A; Gross,M; Gillespie,G,Y; Roizman,B. 2002. Second-site mutation outside of the U(S)10-12 domain of Delta gamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially. restores neurovirulence.  JOURNAL OF VIROLOGY. Vol. 76, no. 3. (February): 942-949.
  • Cassady KA and Whitley RJ. 2002. Viral Central Nervous System Infections. In Clinical Virology. 2nd ed. Washington DC: ASM Press.
  • Cassady KA and Whitley RJ. 1999. Acute and Chronic Encephalitis. In Infectious Diseases. London: Mosby Lynton House.
  • Cassady,K,A; Gross,M; Roizman,B. 1998. The second-site mutation in the herpes simplex virus recombinants lacking the gamma(1)34.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2 alpha.  JOURNAL OF VIROLOGY. Vol. 72, no. 9. (September): 7005-7011.
  • Cassady KA and Whitley RJ. 1997. Central Nervous System Infections. In Clinical Virology. New York: Churchill Livingstone.
  • Cassady KA and Whitley RJ. 1996. Pathogenesis and Pathophysiology of Viral Central Nervous System Infections. In Infections of the Central Nervous System. New York: Raven Press.
  • Cassady Ka and Whitley RJ. New therapeutic approaches to alphaherpesvirus infections.  Journal of Antimicrobial Chemotherapy (1997) 39, 119-128.
  • Dziurzynski K, Chang S, Heimberger A., Kalejta RF, MeGregor Dallas SR, Smit MJ, Soroceanu JL, Cobbs CS and the CMV and Glioma Symposium (JC. Alwine, W Britt, KA Cassady, S Chang, M.D., EA Chiocca, CS Cobbs, K Dziurzynski, L Fortuato, AB Heimberger, RF Kalejta, TF Kowalik, CH Kwon, SR McGregor Dallas, L Matlaf, D. Mitchell, R Price, MJ Smit, C Soderberg-Naucler, and J. Liliana Sococeanu. Consensus on the role of human cytomegalovirus in glioblastoma.  Neuro Oncol. (2012, Mar) 14(3):246-55.
  • Cassady KA, Newland JG and Saiman L. Encouraging Antiobiotic Development and Endorsing Conservation: Tandem approaches to our declining antibiotic reserves.  Infection Control and Hospital Epidemiology (2015, Dec) in press.
  • Cassady KA and Olson J. 0. Anti-Infective Agents. In Clinical Pharmacology Made Ridiculously Simple.
  • Cassady KA, Gross M and Roizman B. The herpes simplex virus US11 protein effectively compensates for the (1)34.5 gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of translation initiation factor eIF-2.  Journal of Virology (1998) 72: 8620-8626.
  • Cassady KA and Whitley RJ. 0. Viral Central Nervous System Infections. In Clinical Virology.
  • Cassady KA and Whitley RJ. Encephalitis : Thoughts of Pathogenesis and Diagnostics. Infectious Disease of the CNS.  Current Infectious Disease Reports (1999) 1: 178-186.
  • Joshua D. Jackson, Adrienne McMorris, Jennifer Coleman, Justin C. Roth, Stephen Carroll, G. Yancey Gillespie, James M. Markert and KA Cassady. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.  Gene Therapy (2014, Nov.) 21(11):984-90.
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000